Publications tagged with “cohort study”

A study that selects exposed and unexposed populations to follow for occurrences of the outcome of interest.

• Kappelman MD, Brensinger CM, Parlett LE, Hurtado-Lorenzo A, Lewis JD. Prevalence of pediatric inflammatory bowel disease in the United States: pooled estimates from three administrative claims data sources. Gastroenterology. 2025; 168 (5) :980-2 doi: 10.1053/j.gastro.2024.11.004.
• Long MD, Ball K, Bocage C, Kappelman MD, Pipkin CA, Parlett LE. Novel therapies for inflammatory bowel disease and risks for non-melanoma skin cancer. Podium presented at: 2025 Digestive Disease Week; May 03 – May 06, 2025; San Diego, CA, US .
• Hoffman P, Parlett LE, Beachler DC, et al. Validation of claims-based algorithms for newly diagnosed juvenile idiopathic arthritis using machine learning methods. Poster presented at: 2023 American College of Rheumatology (ACR) Convergence; Nov 10 – Nov 15, 2023; San Diego, CA, US https://acr23.eventscribe.net/searchGlobal.asp?mode=Presentations&SearchQuery=0353.
• Cook M, Beachler DC, Parlett LE, Cochetti PT, Finkle WD, Lanes S. Abstract 5050: testosterone supplementation in relation to prostate cancer in a us commercial insurance claims database. Poster presented at: 2019 American Association for Cancer Research (AACR) Annual Meeting; Mar 29 – Apr 03, 2019; Atlanta, GA, US https://aacrjournals.org/cancerres/article/79/13_Supplement/5050/636990/Abstract-5050-Testosterone-supplementation-in. doi: 10.1158/1538-7445.AM2019-5050.
• Parlett LE, Ball K, Pipkin CA, Kappelman MD, Bocage C, Long MD. Compared to thiopurines and tumor necrosis factor inhibitors novel biologics are associated with reduced risk of non-melanoma skin cancer among patients with inflammatory bowel disease. Poster presented at: 2024 International Society for Pharmacoepidemiology Annual Meeting; Aug 24 – Aug 28, 2024; Berlin, DE .
• Anthony MS, Djebarri L, Beachler DC, et al. Risk of anaphylaxis among new users of glucagon-like peptide-1 receptor agonists (GLP-1 ras). Poster presented at: 2023 American Diabetes Association Scientific Sessions; Jun 23 – Jun 26, 2023; San Diego, CA, US https://diabetesjournals.org/diabetes/article/72/Supplement_1/846-P/150217/846-P-Risk-of-Anaphylaxis-among-New-Users-of. doi: 10.2337/db23-846-P.
• Lewis JD, Brensinger CM, Parlett LE, Hurtado-Lorenzo A, Kappelman MD. Provider specialization in inflammatory bowel diseases: quality of care and outcomes. Clin Gastroenterol Hepatol. 2024; 22 (12) :2475-86.e14 doi: 10.1016/j.cgh.2024.05.024.
• Long MD, Parlett LE, Lewis JD, et al. Corticosteroids but not anti-TNF are associated with increased COVID-19 complications in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2024; 30 (8) :1345–52 doi: 10.1093/ibd/izad176.
• Adimadhyam S, Lewis JD, Simon AL, et al. Real-world evidence comparing tofacitinib and vedolizumab in anti-TNF-experienced patients with ulcerative colitis. Inflamm Bowel Dis. 2024; 30 (4) :554-62 doi: 10.1093/ibd/izad115.
• Anthony MS, Aroda VR, Parlett LE, et al. Risk of anaphylaxis among new users of GLP-1 receptor agonists: a cohort study. Diabetes Care. 2024; 47 (4) :712-9 doi: 10.2337/dc23-1911.
• Horton DB, Yang Y, Neikirk AL, et al. Impact of the COVID-19 pandemic on the management of juvenile idiopathic arthritis: analysis of United States commercial insurance data. J Clin Rheumatol. 2023; 29 (8) :388-95 doi: 10.1097/RHU.0000000000002035.
• Kappelman MD, Lewis JD, Zhang X, et al. Comparing patient-reported outcomes among anti-TNF-experienced patients with crohn's disease initiating vedolizumab versus ustekinumab. Dig Dis Sci. 2023; 68 (8) :3413-20 doi: 10.1007/s10620-023-07942-0.
• Kappelman MD, Long MD, Zhang X, et al. Comparing patient-reported outcomes among anti-TNF experienced patients with ulcerative colitis initiating vedolizumab versus tofacitinib. Crohns Colitis 360. 2023; 5 (3) :otad031 doi: 10.1093/crocol/otad031.
• Kappelman MD, Adimadhyam S, Hou L, et al. Real-world evidence comparing vedolizumab and ustekinumab in antitumor necrosis factor-experienced patients with crohn's disease. Am J Gastroenterol. 2023; 118 (4) :674-84 doi: 10.14309/ajg.0000000000002068.
• Horton DB, Neikirk AL, Yang Y, et al. Childhood asthma diagnoses declined during the COVID-19 pandemic in the United States. Respir Res. 2023; 24 (1) :72 doi: 10.1186/s12931-023-02377-7.
• Parlett LE, Ma Q, Shi Q, et al. Burden of non-alcoholic steatohepatitis among children with type 2 diabetes mellitus. Diabetol Metab Syndr. 2021; 13 (1) :47 doi: 10.1186/s13098-021-00665-0.
• Cook M, Beachler DC, Parlett LE, et al. Testosterone therapy in relation to prostate cancer in a U.S. commercial insurance claims database. Cancer Epidemiol Biomarkers Prev. 2020; 29 (1) :236-45 doi: 10.1158/1055-9965.EPI-19-0619.
• Parlett LE, Gordon A, Sylwestrzak G, White J, Power T, Barron J. Hospitalization rates and costs among real world users of sacubitril/valsartan versus other heart failure medications. Podium presented at: 2018 American Heart Association Scientific Sessions; Nov 10 – Nov 12, 2018; Chicago, IL, US .
• Beachler DC, Parlett LE, Lanes S, Hoover R, Cook M. Testosterone supplementation in relation to prostate cancer in a us commercially-insured claims database. Podium presented at: 2018 International Society for Pharmacoepidemiology International Conference on Pharmacoepidemiology & Therapeutic Risk Management; Aug 22 – Aug 26, 2018; Praha 4-Nusle, CZ .
• Barrett ES, Parlett LE, Sathyanarayana S, Redmon J, Nguyen RH, Swan SH. Prenatal stress as a modifier of associations between phthalate exposure and reproductive development: results from a multicentre pregnancy cohort study. Paediatr Perinat Epidemiol. 2016; 30 (2) :105-14 doi: 10.1111/ppe.12264.
• Barrett ES, Parlett LE, Swan SH. Stability of proposed biomarkers of prenatal androgen exposure over the menstrual cycle. J Dev Orig Health Dis. 2015; 6 (2) :149-57 doi: 10.1017/S2040174414000646.
• Barrett ES, Parlett LE, Redmon J, Swan SH. Evidence for sexually dimorphic associations between maternal characteristics and anogenital distance, a marker of reproductive development. Am J Epidemiol. 2014; 179 (1) :57-66 doi: 10.1093/aje/kwt220.
• Barrett ES, Parlett LE, Sathyanarayana S, et al. Prenatal exposure to stressful life events is associated with masculinized anogenital distance (agd) in female infants. Physiol Behav. 2013; 114-115 :14-20 doi: 10.1016/j.physbeh.2013.03.004.
• Parlett LE, Bowman JD, van Wijngaarden E. Evaluation of occupational exposure to magnetic fields and motor neuron disease mortality in a population-based cohort. J Occup Environ Med. 2011; 53 (12) :11-17 doi: 10.1097/JOM.0b013e318237a1d0.